Cue Biopharma (NASDAQ: CUE) Secures $7.5M Milestone from Boehringer Ingelheim Partnership
Key Developments Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company specializing in innovative therapies targeting memory T cell subsets, announced it will receive a $7.5 million preclinical milestone payment. This payment is part of its ongoing collaboration and license agreement with Boehringer Ingelheim, following the selection and approval of the first compound for lead optimization. The milestone payment is expected to be disbursed in May 2026, marking an important…
